Optimized for Minimal Sample Input (Without Compromising Accuracy)
With Targeted EM-seq, you no longer have to worry about insufficient cfDNA for comprehensive analysis. This technology enables reliable methylation profiling from as little as 10 ng of cfDNA—ideal for liquid biopsy applications where sample quantities are often scarce. Despite working with minimal material, Targeted EM-seq delivers precise and reproducible methylation patterns, ensuring you can confidently proceed with your analysis without the risk of sample wastage.
Preserving DNA Integrity (Minimizing Sample Degradation)
Traditional bisulfite sequencing relies on harsh chemical treatments that can damage fragile DNA, especially in low-input samples. Targeted EM-seq, however, uses a gentle enzymatic conversion method that preserves the integrity of the DNA throughout the process. This non-destructive approach ensures high-quality sequencing results, where the preservation of genetic material leads to more accurate and reliable data. You can trust that your analysis won't be compromised by sample degradation.
Unmatched Sensitivity and Resolution (Even in Low-Abundance Samples)
Targeted EM-seq utilizes Twist Bioscience's targeted methylation capture probes, enabling the detection of over 3.8 million CpG methylation sites across the human genome. This high sensitivity allows you to detect even subtle methylation changes, crucial for research in low-abundance samples. Whether you're identifying biomarkers or studying disease mechanisms, Targeted EM-seq provides the level of detail required to uncover meaningful insights, ensuring that no critical data is overlooked.
Comprehensive Genomic Coverage (For a Holistic Epigenetic Understanding)
Targeted EM-seq covers 84.2% of the CpG sites in the human genome, ensuring that your methylation analysis captures the most biologically relevant regions. This broad genomic coverage allows you to identify disease-specific methylation markers, explore epigenetic modifications, and gain a more comprehensive understanding of how methylation patterns relate to various health conditions. This extensive data coverage supports more robust findings and enables you to advance your research with a fuller epigenetic picture.
